Antiviral and non-antiviral general treatments for oro-facial and genital herpes (pregnancy and neonates excluded);Traitements généraux, antiviraux ou non, dans la prise en charge de l'herpès oro-facial et génital (grossesse et nouveau-né exclus)

Annales de Dermatologie et de Venereologie

Volumn 129, Issue 4 II, 2002, Pages 625-634

  Guillaume, J C ^a  

^a Pasteur Hospital   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; FAMCICLOVIR; FOSCARNET SODIUM; ORAVIR; VALACICLOVIR;

CONFERENCE PAPER; DRUG EFFICACY; GENITAL HERPES; HERPES SIMPLEX; LATENT VIRUS INFECTION; SENSORY GANGLION; VIRUS ADSORPTION; VIRUS RESISTANCE;

ACYCLOVIR; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HERPES GENITALIS; HERPES LABIALIS; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; INTERFERON-ALPHA; RECURRENCE; STOMATITIS, HERPETIC; VALINE;

EID: 0036277536     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (97)

1. Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy
2. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpes virus infections
3. Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpes virus infections
4. Antiviral drugs
5. Efficacité du cidifovir dans un herpès cutané résistant à l'aciclovir et au foscarnet chez un malade séropositif pour le VIH
6. Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection
7. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects
8. Intravenous acyclovir treatment for primary genital herpes
9. Intravenous acyclovir for the treatment of primary genital herpes
10. Intravenous acyclovir therapy of first episodes of genital herpes: A multicenter double-blind, placebo-controled trial
11. Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: Results of topical, intravenous and oral therapy
12. A randomized double-blind, comparative trial comparing high- and standard-dose oral acyclovir for first-episode genital herpes infections
13. Efficacy of combined treatment with oral and topical acyclovir in first episode genital herpes
14. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection
15. Valaciclovir en el tratamiento de la primoinfeccion por el virus del herpes genital: Estudio comparativo
16. Risk of recurrence after treatment of first-episode genital herpes with intravenous acyclovir
17. Treatment of first episode genital HSV with oral acyclovir: Long term follow-up of recurrence
18. Acyclovir in first attacks of genital herpes and prevention of recurrences
19. Efficacy of oral treatment with acyclovir and co-trimoxazole in first episode genital herpes
20. Treatment of first-attack genital herpes-acyclovir versus inosine pranobex
21. Comparison of intramuscular recombinant alpha interferon (rINF-2A) with topical acyclovir for the treatment of first-episode herpes genitalis and prevention of recurrence
22. Oral acyclovir in the treatment of genital herpes. Preliminary report of a multicenter trial
23. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes
24. Controlled trial of oral acyclovir in the therapy of recurrent herpes simplex genitalis. A preliminary report
25. Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial
26. Treatment of recurrent genital herpes simplex infections with oral acyclovir
27. Oral acyclovir for episodic treatment of recurrent genital herpes
28. Etude d'équivalence entre une formulation à libération prolongée d'acyclovir (Genvir) et le Zovirax® dans le traitement des récurrences d'herpès génital
29. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis
30. A randomized, placebo-controlled comparison of oral valaciclovir and aciclovir in immunocompetent patients with recurrent genital herpes infections
31. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: A randomised, double blind clinical trial
32. A double-blind, randomized study assessing the equivalence of valacyclovir 1,000 mg once daily versus 500 mg twice daily in the episodic treatment of recurrent genital herpes
33. Patient-initiated, twice - Daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial Canadian Famciclovir Study Group
34. Famcicloir versus acyclovir in immunocompetent patients with recurrent genital herpes infections; an equivalence, randomized, double-blind clinical trial
35. Suppression of frequently recurring genital herpes. A place-bocontrolled double-blind trial of oral acyclovir
36. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection
37. Prophylactic oral acyclovir in recurrent genital herpes
38. Recurrent genital herpes suppressed by oral acyclovir: A multicenter double blind trial
39. Oral acyclovir suppression of recurrent genital herpes: A double-blind, placebo-controlled, crossover study
40. Acyclovir prophylaxis of recurrent genital herpes: Randomised placebo-controlled crossover study
41. Double-blind comparison of weekend and daily regimens of oral acyclovir for suppression of recurrent genital herpes
42. Long-term oral acyclovir treatment prevents recurrent genital herpes
43. Prolonged continuous versus intermittent oral acyclovir treatment in normal adults with frequently recurring genital herpes simplex virus infection
44. Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes
45. Acyclovir suppression of frequently recurring genital herpes. Efficacy and diminishing need during successive years of treatment
46. Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial
47. Double-blind, placebo-controlled trial comparing long-term suppressive with short-term oral acyclovir therapy for management of recurrent genital herpes
48. Chronic suppression for six months compared with intermittent lesional therapy of recurrent genital herpes using oral acyclovir: Effects on lesions and nonlesional prodromes
49. Long-term suppression with oral acyclovir of recurrent herpes simplex virus infections in otherwise healthy patients
50. Suppression of recurrent genital herpes by single daily dosages of acyclovir
51. One-year suppression of frequent recurrences of genital herpes with oral acyclovir
52. Oral acyclovir suppressive therapy in severe recurrent genital herpes. A double-blind, placebo-controlled cross-over study
53. Prolonged continuous acyclovir treatment of normal adults with frequently recurring genital herpes simplex virus infection
54. Long-term suppression of recurrent genital herpes with acyclovir. A 5-year benchmark
55. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir
56. The effect of suppressive oral acyclovir on the psychological morbidity associated with recurrent herpes
57. Valaciclovir for the suppression of recurrent genital HSV infection: A placebo-controlled study of once daily therapy
58. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: A large-scale dose range-finding study
59. Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection
60. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial
61. Oral famciclovir for the suppression of recurrent genital herpes
62. Recurrence and resistance patterns of herpes simplex virus following cessation of > or = 6 years of chronic suppression with acyclovir
63. Acyclovir vs isoprinosine (immunovir) for suppression of recurrent genital herpes simplex infection
64. Does the extract of the plant Echinacea purpurea influence the clinical course of recurrent genital herpes
65. Suppression of herpes simplex virus infections with oral lithium carbonate - A possible antiviral activity
66. Levamisole in patients with recurrent herpes infection
67. Treatment of herpes simplex gingivostomatitis with aciclovir in children
68. Oral acyclovir and herpes labialis: A randomized double-blind, placebo-controlled study
69. Treatment of recurrent herpes simplex labialis with oral acyclovir
70. Oral acyclovir in the suppression of recurrent non-genital herpes simplex virus infection
71. Oral acyclovir to suppress frequently recurrent herpes labialis. A double-blind, placebo-controlled trial
72. Lysine as a prophylactic agent in the treatment of recurrent herpes simplex labialis
73. Lysine prophylaxis in recurrent herpes simplex labialis: A double-blind, controlled crossover study
74. Failure of lysine in frequently recurrent herpes simplex infection. Treatment and prophylaxis
75. A double-blind, controlled trial of levamisole in the treatment of recurrent herpes labialis
76. Prevention of recurrences in frequently relapsing herpes labialis with thymopentin. A randomized double-blind placebo-controlled multicenter study
77. The natural history of ultraviolet radiation-induced herpes simplex labialis and response to therapy with peroral and topical formulations of acyclovir
78. Acyclovir prevents reactivation of herpes simplex labialis in skiers
79. Oral acyclovir in prevention of herpes labialis. A randomized, double-blind, multicentered clinical trial
80. Peroral famciclovir in the treatment of experimental ultraviolet radiation-induced herpes simplex labialis: A double-blind, doseranging, placebo-controlled, multicenter trial
81. Complications of carbon dioxide laser resurfacing. An evaluation of 500 patients
82. Use of valacyclovir for herpes simplex virus 1 (HSV1) prophylaxis after facial resurfacing: A randomized clinical trial of dosing regimens
83. Famciclovir as antiviral prophylaxis in laser resurfacing procedures
84. Famciclovir prophylaxis of herpes simplex virus reactivation after laser skin resurfacing
85. Treatment of eczema herpeticum with oral acyclovir
86. A double-blind, placebo-controlled trial of continuous acyclovir therapy in recurrent erythema multiforme
87. Oral acyclovir for treatment of first-episode herpes simplex virus proctitis
88. A recombinant glycoprotein vaccine herpes simplex virus type 2: Safety and immunogenicity
89. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection
90. Recombinant glycoprotein vaccine for the prevention of genital HSV2 infection: Two randomized controlled trials
91. Ineffectiveness and toxicity of BCG vaccine for the prevention of recurrent genital herpes
92. Gul feber-vaccination som profylakse ved herpes labialis
93. Behandlung des rezidivierenden herpes labialis mit einer herpessimplex-typ-I-subunit-vakzine. Eine prospektive randomisierte doppelblind-kontrollierte Multicenter-Studie
94. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoprotein D and B: Results of a placebo-controlled vaccine trial
95. Multicentre clinical trial with herpes simplex virus vaccine in recurrent herpes infection
96. The efficacy and safety of Skinner herpes simplex vaccine towards modulation of herpes genitalis: Report of a prospective double-blind-placebo-controlled trial
97. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes